Table 1.

Characteristics of the all study patients.(n = 1410)

Characteristics	Number of Patients (%)
Age, year
18–35	25 (1.8)
35–45	64 (4.5)
45–55	223 (15.8)
55–65	328 (23.3)
65–75	434 (30.8)
> 75	336 (23.8)
Mean Age (standard deviation)	65.09 (12.65)
Female	780 (55.3%)
Iron dosage during treatment
0 mg/month	1127 (79.9)
0-300 mg/month	162 (11.5)
300-400 mg/month	31 (2.2)
> 400 mg/month	90 (6.4)
Mean Iron treatment duration, months/year (standard deviation)a	3.09 (2.17)
Permanent venous catheter on index day	49 (3.5)
Comorbidities within 2 years before index date
Hypertension	1142 (81.0)
Ischemic heart disease	690 (48.9)
Stroke	278 (19.7)
Diabetes mellitus	849 (60.2)
Chronic pulmonary disease	317 (22.5)
Heart failure	437 (31.0)
Liver cirrhosis	102 (7.2)
Connective tissue disease	215 (15.2)
Malignancy	244 (17.3)
Polycystic kidney disease	13 (0.9)

^apatients without intravenous iron treatment were excluded